Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency
Search results
1448 results
-
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
-
Eliglustat for treating type 1 Gaucher disease (HST5)
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
-
Migalastat for treating Fabry disease (HST4)
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
-
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children
-
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit
-
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
-
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
-
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
-
Metreleptin for treating lipodystrophy (HST14)
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults
-
Stye: antimicrobial prescribing
In development [GID-NG10167] Expected publication date: TBC
-
Blepharitis: antimicrobial prescribing
In development [GID-NG10168] Expected publication date: TBC
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
SACT
In development [GID-NG10184] Expected publication date: TBC
-
Clostridioides difficile infection: antimicrobial prescribing
In development [GID-NG10144] Expected publication date: 23 July 2021
-
Tobacco: preventing uptake, promoting quitting and treating dependence (update)
In development [GID-NG10086] Expected publication date: 01 September 2021
-
Mental wellbeing at work
In development [GID-NG10140] Expected publication date: 15 December 2021
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 17 May 2022
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 09 February 2022
-
Looked-after children and young people
In development [GID-NG10121] Expected publication date: 27 September 2021
-
Vaccine uptake in the general population
In development [GID-NG10139] Expected publication date: 06 April 2022
-
Social and emotional wellbeing in secondary education (PH20)
This guideline covers interventions to support social and emotional wellbeing among young people aged 11–19 years who are in full-time education. It aims to promote good social, emotional and psychological health to protect young people against behavioural and health problems.
-
Smoking prevention in schools (PH23)
This guideline covers smoking prevention interventions that are delivered in schools or other educational institutions. It aims to prevent children and young people aged under 19 from taking up smoking.
-
Mental wellbeing at work (PH22)
This guideline covers how to create the right conditions to support mental wellbeing at work. The aim is to promote a culture of participation, equality and fairness in the workplace based on open communication and flexible working.
-
Physical activity in the workplace (PH13)
This guideline covers how to encourage employees to be physically active. The aim is to increase the working population’s physical activity levels.
-
Smoking: preventing uptake in children and young people (PH14)
This guideline covers anti-smoking mass-media campaigns, for example, on TV, in newspapers and online. It also covers measures to prevent tobacco being sold to children and young people. The aim is to help prevent children and young people from taking up smoking.
-
Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)
This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.
-
Social and emotional wellbeing in primary education (PH12)
This guideline covers approaches to promoting social and emotional wellbeing in children aged 4 to 11 years in primary education. It includes planning and delivering programmes and activities to help children develop social and emotional skills and wellbeing. It also covers identifying signs of anxiety or social and emotional problems in children and how to address them.
-
Obesity: working with local communities (PH42)
This guideline covers how local communities, with support from local organisations and networks, can help prevent people from becoming overweight or obese or help them lose weight. It aims to support sustainable and community-wide action to achieve this.
-
Hepatitis B and C testing: people at risk of infection (PH43)
This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.
-
Looked-after children and young people (PH28)
This guideline covers how organisations, professionals and carers can work together to deliver high quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and enjoy the same opportunities in life as their peers.
-
Smoking: stopping in pregnancy and after childbirth (PH26)
This guideline covers support to help women stop smoking during pregnancy and in the first year after childbirth. It includes identifying women who need help to quit, referring them to stop smoking services and providing intensive and ongoing support to help them stop. The guideline also advises how to tailor services for women from disadvantaged groups in which smoking rates are high.
-
Smoking: harm reduction (PH45)
This guideline covers reducing harm from smoking. It aims to help people, particularly those who are highly dependent on nicotine, who:
-
BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups (PH46)
This guideline covers the link between body mass index (BMI) and waist circumference and the risk of disease among adults from black, Asian and other minority ethnic groups in the UK. The aim was to determine whether lower cut-off points should be used for these groups as a trigger for lifestyle interventions to prevent conditions such as diabetes, myocardial infarction or stroke.
-
Smokeless tobacco: South Asian communities (PH39)
This guideline covers people living in England with ancestral links to Bangladesh, India, Nepal, Pakistan or Sri Lanka who use traditional South Asian varieties of smokeless tobacco. The aim is to help them stop using tobacco that is placed in the mouth or nose (but not burned). It does not include oral snuff products that are sucked.
-
Developing and updating local formularies (MPG1)
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
-
Patient group directions (MPG2)
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
-
Smoking: acute, maternity and mental health services (PH48)
This guideline covers helping people to stop smoking in acute, maternity and mental health services. It promotes smokefree policies and services and recommends effective ways to help people stop smoking or to abstain from smoking while using or working in secondary care settings.
-
Behaviour change: individual approaches (PH49)
This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.
-
Smoking: workplace interventions (PH5)
This guideline covers how employers can encourage and support employees to stop smoking. It aims to reduce the number of people who smoke or are exposed to second-hand smoke and the rate of diseases and conditions caused by smoking.
-
Domestic violence and abuse: multi-agency working (PH50)
This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.
-
Contraceptive services for under 25s (PH51)
This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.
-
Weight management: lifestyle services for overweight or obese adults (PH53)
This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.
-
Human and animal bites: antimicrobial prescribing (NG184)
This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.
-
Leg ulcer infection: antimicrobial prescribing (NG152)
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
-
Insect bites and stings: antimicrobial prescribing (NG182)
This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.
-
Impetigo: antimicrobial prescribing (NG153)
This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.